Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Changes in Stockholders Equity

v3.21.1
Consolidated Statements of Changes in Stockholders Equity - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Beginning Balance, Shares at Dec. 31, 2019 11,949,042        
Beginning Balance, Amount at Dec. 31, 2019 $ 1,194 $ 32,218,643 $ (176,717) $ (23,241,835) $ 8,801,285
Shares issued on conversion of convertible debentures, shares 123,399        
Shares issued on conversion of convertible debentures $ 12 395,241     395,253
Common stock issued to settle deferred purchase consideration,shares 204,437        
Common stock issued to settle deferred purchase consideration $ 21 842,411     842,432
Common stock issued to settle liabilities        
Restricted stock awards        
Stock based compensation expense   118,818     118,818
Foreign currency translation adjustment     (112,030)   (130,230)
Net income (loss)       157,609 157,609
Ending Balance, Shares at Mar. 31, 2020 12,276,878        
Ending Balance, Amount at Mar. 31, 2020 $ 1,227 33,575,113 (288,747) (23,084,226) 10,203,367
Beginning Balance, Shares at Dec. 31, 2020 20,029,834        
Beginning Balance, Amount at Dec. 31, 2020 $ 2,003 53,064,919 267,948 (33,178,517) 20,156,353
Proceeds from warrants exercised, shares 1,488,809        
Proceeds from warrants exercised $ 149 3,909,832     3,909,981
Common stock issued to settle liabilities, shares 467,990        
Common stock issued to settle liabilities $ 47 2,676,854     2,676,901
Restricted stock awards, shares 24,476        
Restricted stock awards $ 2 139,998     140,000
Stock based compensation expense   288,968     288,968
Foreign currency translation adjustment     (344,088)   (344,088)
Net income (loss)       (609,579) (609,579)
Ending Balance, Shares at Mar. 31, 2021 22,011,109        
Ending Balance, Amount at Mar. 31, 2021 $ 2,201 $ 60,080,571 $ (76,140) $ (33,788,096) $ 26,218,536